Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa.
Youngji JoLise JamiesonIjeoma EdokaLawrence LongSheetal SilalJuliet R C PulliamHarry MoultrieIan SanneGesine Meyer-RathBrooke E NicholsPublished in: Open forum infectious diseases (2021)
The use of remdesivir for nonventilated patients and dexamethasone for ventilated patients is likely to be cost-saving compared with standard care by reducing ICU days. Further efforts to improve recovery time with remdesivir and dexamethasone in ICUs could save lives and costs in South Africa.
Keyphrases
- south africa
- end stage renal disease
- ejection fraction
- newly diagnosed
- intensive care unit
- chronic kidney disease
- low dose
- healthcare
- coronavirus disease
- prognostic factors
- peritoneal dialysis
- sars cov
- hiv positive
- palliative care
- chronic pain
- pain management
- mechanical ventilation
- human immunodeficiency virus
- replacement therapy